- Home
- PTN vs LVTX Comparison
PTN vs LVTX Comparison
Compare PTN & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTN
- LVTX
- Stock Information
- Founded
- PTN 1986
- LVTX 2016
- Country
- PTN United States
- LVTX Netherlands
- Employees
- PTN N/A
- LVTX N/A
- Industry
- PTN Biotechnology: Pharmaceutical Preparations
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PTN Health Care
- LVTX Health Care
- Exchange
- PTN Nasdaq
- LVTX Nasdaq
- Market Cap
- PTN 25.4M
- LVTX 27.9M
- IPO Year
- PTN 1993
- LVTX 2021
- Fundamental
- Price
- PTN $1.00
- LVTX $0.96
- Analyst Decision
- PTN Strong Buy
- LVTX Buy
- Analyst Count
- PTN 1
- LVTX 3
- Target Price
- PTN $7.00
- LVTX $3.33
- AVG Volume (30 Days)
- PTN 1.7M
- LVTX 27.7K
- Earning Date
- PTN 02-13-2025
- LVTX 03-19-2025
- Dividend Yield
- PTN N/A
- LVTX N/A
- EPS Growth
- PTN N/A
- LVTX N/A
- EPS
- PTN N/A
- LVTX N/A
- Revenue
- PTN $350,000.00
- LVTX $7,345,000.00
- Revenue This Year
- PTN N/A
- LVTX $16.68
- Revenue Next Year
- PTN N/A
- LVTX N/A
- P/E Ratio
- PTN N/A
- LVTX N/A
- Revenue Growth
- PTN N/A
- LVTX N/A
- 52 Week Low
- PTN $0.68
- LVTX $0.85
- 52 Week High
- PTN $3.99
- LVTX $6.47
- Technical
- Relative Strength Index (RSI)
- PTN 50.51
- LVTX 46.74
- Support Level
- PTN $0.99
- LVTX $0.85
- Resistance Level
- PTN $1.08
- LVTX $0.98
- Average True Range (ATR)
- PTN 0.14
- LVTX 0.05
- MACD
- PTN 0.01
- LVTX 0.01
- Stochastic Oscillator
- PTN 35.59
- LVTX 59.72
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.